TACE 联合利卡汀治疗对肝癌患者病理指标及CTCs 检出数的影响

Effect of transcatheter arterial chemoembolization combined with Licartin on pathological indicators and number of circulating tumor cells in liver cancer patients

摘要:

目的 探讨经导管肝动脉化疗栓塞术（TACE）联合利卡汀治疗对肝癌患者病理指标及循环肿瘤细胞（CTCs）检出数的影响。方法 选取2014 年1 月-2016 年6 月在沭阳中山医院介入科接受治疗的120例原发性肝癌患者作为该研究对象。根据患者治疗意愿将其分为对照组和实验组，其中对照组52 例，仅给予经导管肝动脉化疗栓塞术治疗，实验组68 例，在对照组治疗基础上联合利卡汀治疗。比较两组患者治疗前后肿块大小、甲胎蛋白（AFP）水平、血象、肝功能、CTCs 以及CD147 不同分子表型患者。结果 治疗后两组患者肿瘤大小相比差异无统计学意义（P >0.05）；治疗后，两组AFP 水平比较，差异有统计学意义（P <0.05），实验组低于对照组；治疗后，两组白细胞计数和丙氨酸转氨酶比较，差异有统计学意义（P <0.05），白细胞计数实验组低于对照组，丙氨酸转氨酶实验组高于对照组；治疗后两组CTCs 检出数目比较，差异有统计学意义（P <0.05），均降低，且实验组低于对照组；实验组CD147 2 种表型患者治疗前后CTCs 数目变化值间比较，差异有统计学意义（P <0.05）；对照组CD147 2 种表型患者治疗前后CTCs 数目变化值间比较，差异无统计学意义（P >0.05）；两组患者不良反应发生率比较，差异无统计学意义（P >0.05）。结论 利卡汀联合TACE治疗肝癌，临床效果优于单纯TACE 治疗，此外，利卡汀对于CD147+ 肝癌患者治疗效果优于CD147- 患者。

Abstract:

Objective To explore the effect of transcatheter arterial chemoembolization (TACE) combined with Licartin on pathological indicators and number of circulating tumor cells (CTCs) in liver cancer patients. Methods Totally 120 cases of primary liver cancer patients treated in our hospital from January 2014 to June 2016 were enrolled as research objects. They were divided into experimental group and control group according to treatment. The 52 cases in the control group were treated with TACE and the 68 cases in the experimental group were treated with Licartin and TACE. The tumor size, AFP level, blood routine, liver function, number of CTCs and number of CTCs in patients with different molecular phenotypes of CD147 were compared before and after treatment between the two groups. Results After treatment, the tumor size of the two groups had no significant difference (P > 0.05). After treatment, the AFP level significantly decreased in both groups, and was significantly lower in the experimental group than in the control group (P < 0.05). After treatment, the platelet count in the experimental group was significantly lower than that in the control group and alanine aminotransferase was significantly higher than that in the control group (P < 0.05). After treatment, the number of CTCs detected in the two groups was significantly decreased, and the number of CTCs in the experimental group was significantly smaller than that in the control group (P < 0.05). The changes of the number of CTCs before and after treatment had significant difference between the patients with two different CD147 phenotypes in the experimental group (P < 0.05), while there was no significant difference in the control group (P > 0.05). There were no statistical differences in the incidences of adverse reactions between the two groups (P > 0.05). Conclusions For the treatment of liver cancer patients, Licartin combined with TACE has better clinical effect than TACE treatment. Licartin would be suggested for CD147+ HCC patients, but not for CD147- patients.